GSK names head of infectious diseases R&D unit

显然是个中国人。人家没改洋名字，不也照样出人头地。

British drugmaker GlaxoSmithKline said Wednesday it has appointed Zhi Hong
to lead a new research unit aimed at the discovery of therapies for
infectious diseases.

Hong, currently executive vice president and chief scientific officer for
San Diego-based Ardea Biosciences, will assume the new position effective
April 23.

In his new role, Hong will oversee discovery operations for treatments for
diseases such as HIV, AIDS and viral hepatitis and for bacterial resistance
to currently marketed antibiotics.

GSK officials said they have yet to determine where Hong will be based but
that it will likely be either in Pennsylvania or in Research Triangle Park.

Hong will run GSK's Center of Excellence for Drug Discovery for infectious
diseases, a research and development facility being developed specifically
to target infectious disease drug research and development.

GSK's research and development operations include nine CEDDs organized by
therapeutic area or technology.

FDA enjoined from approving other amlodipine until 4/13

Court asks FDA to provide argument by the 11th. FDA says to ask interested parties first. Looks like it's truly an issue without clear answer

Pfizer filed two citizen petitions today

Regarding Amlodipine, trying to enforce its Pedaitric exclusivity.
No word on Apotex yet.

Amlodipine Follow-up

1. Apotex claims there is no exclusivity for anyone
2. Mylan launched around noon, claiming it has exclusivity
3. Pfizer launched through Greenstone in the afternoon and claimed it would still seek all legal routes to address the situation

What an industry!

Amlodipine

After two district courts ruled in favor of Pfizer, Court of Appeals today wreck a havoc and invalidated the Amlodipine patent. What's going on?

Pfizer won Celecoxib case

Teva to appeal; right now looks like generic can't launch until 2015.

Ranbaxy dropped out of Merck bid

Per AP news today.

Merck KGaA Contender Shortlist

per an Indian news paper, Teva, Actavis, Mylan, and Ranbaxy are shortlisted. Surprised to see Teva on this list too.

Indian companies after Merck generic business

Ranbaxy, Cipla both are working on this.

Will Merck KGaA become an Indian company?

Schering Plough Acquires Organon

Schering Plough pays Akzo 11 billion euros.

近期的制药业的消息

Merck获得了投资届的青睐; 主要的投资银行将其评价提升为”购买”.

Wyeth的FDA问题仍然在继续; 受影响的生产设施无法在近期内通过评审

BMS被并购的传言继续; 但是消息传出Sanofi无法就具体条件与其达成协议;

PFIZER大刀阔斧地精简, 称目标为回到收购PHARMACIA以前的水平

十多年来没有仿制药竞争的Inderal LA终于等来了第一只狼, Par前不久宣布其产品获得了批准, 其股票价格也大幅度上涨. 非常有趣的是, 不久后, Mylan也宣布获得了批准, 随即造成Par的估价下跌了大约$1. 上周, Bear Stearns披露Actavis也有类似的ANDA待FDA批准. 这样, 要么一个都没有;要么就来一群. 背后的原因可能有两个: 一是技术的进步, 比如Par应用Glatt的资源; 另一方面, 我觉得这也可能显示出了仿制药行业处境维艰, 有利可图的机会越来越少, 大家不得不铤而走险赶这些不可能的任务.

一些新的PIV出现, 似乎一些主要的化合物专利受到了挑战.

Mylan的amlodipine案子终于有了一个阶段性的结果; Mylan输的干干净净; 虽然Mylan立即表示要上诉, 但他们的时间已经不多了. 恐怕对于大局没有实质影响.